Population Pharmacokinetic–Pharmacodynamic Analysis of a Reserpine-Induced Myalgia Model in Rats

Gloria M. Alfosea-Cuadrado,Javier Zarzoso-Foj,Albert Adell,Alfonso A. Valverde-Navarro,Eva M. González-Soler,Víctor Mangas-Sanjuán,Arantxa Blasco-Serra
DOI: https://doi.org/10.3390/pharmaceutics16081101
IF: 6.525
2024-08-23
Pharmaceutics
Abstract:(1) Background: Fibromyalgia syndrome (FMS) is a chronic pain condition with widespread pain and multiple comorbidities, for which conventional therapies offer limited benefits. The reserpine-induced myalgia (RIM) model is an efficient animal model of FMS in rodents. This study aimed to develop a pharmacokinetic–pharmacodynamic (PK–PD) model of reserpine in rats, linking to its impact on monoamines (MAs). (2) Methods: Reserpine was administered daily for three consecutive days at dose levels of 0.1, 0.5, and 1 mg/kg. A total of 120 rats were included, and 120 PK and 828 PD observations were collected from 48 to 96 h after the first dose of reserpine. Non-linear mixed-effect data analysis was applied for structural PK–PD model definition, variability characterization, and covariate analysis. (3) Results: A one-compartment model best described reserpine in rats (V= 1.3 mL/kg and CL= 4.5 × 10−1 mL/h/kg). A precursor-pool PK–PD model (kin =6.1 × 10−3 mg/h, kp =8.6 × 10−4 h−1 and kout =2.7 × 10−2 h−1) with a parallel transit chain (k0 =1.9 × 10−1 h−1) characterized the longitudinal levels of MA in the prefrontal cortex, spinal cord, and amygdala in rats. Reserpine stimulates the degradation of MA from the pool compartment (Slope1 =1.1 × 10−1 h) and the elimination of MA (Slope2 =1.25 h) through the transit chain. Regarding the reference dose (1 mg/kg) of the RIM model, the administration of 4 mg/kg would lead to a mean reduction of 65% (Cmax), 80% (Cmin), and 70% (AUC) of MA across the brain regions tested.(4) Conclusions: Regional brain variations in neurotransmitter depletion were identified, particularly in the amygdala, offering insights for therapeutic strategies and biomarker identification in FMS research.
pharmacology & pharmacy
What problem does this paper attempt to address?